The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A QTc study of cabazitaxel in patients with advanced solid tumors.
James Lloyd Wade
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Ari David Baron
Consultant or Advisory Role - undisclosed (I)
Sylvie Rottey
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Frederick E. Millard
Research Funding - Sanofi
Gedske Daugaard
No relevant relationships to disclose
Jean-Pascal H. Machiels
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
William A. Conkright
No relevant relationships to disclose
Sunil Sharma
Research Funding - Sanofi
Patricia M.M.B. Soetekouw
Consultant or Advisory Role - Sanofi
Jeffrey Yachnin
Consultant or Advisory Role - Sanofi (I)
Research Funding - Research support
Other Remuneration - undisclosed
Lisa Sengeløv
Consultant or Advisory Role - Sanofi (B)
Research Funding - Sanofi
Other Remuneration - Sanofi
Peter van Veldhuizen
No relevant relationships to disclose
Sanjiv S Agarwala
Honoraria - Sanofi
TX Quyen Nguyen
No relevant relationships to disclose
Mustapha Chadjaa
No relevant relationships to disclose
Pierre Maison-Blanche
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi